Abstract:Background: Treatment for pancreatic neuroendocrine tumors ( PNETs) in patients with unresectable metastatic liver disease has long been a controversial issue. This systematic review aims to summarize the existing evidence concerning the value of primary tumor resection in this group of patients. Methods: A systematic review of the literature and a meta-analysis were performed. The PubMed and Cochrane databases were searched to identify articles that compared palliative primary tumor resection and nonsurgical regimens in patients with PNETs and unresectable liver metastases. Relevant articles were identified in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses ( PRISMA) guidelines. The primary outcome was overall survival. The included studies were evaluated for heterogeneity and publication bias. Results: Overall, 10 studies were included in the analysis. No randomized controlled trials ( RCTs) were identified. These studies included 1,226 patients who underwent a resection of the primary tumor and 1,623 patients who did not undergo surgery. The median overall survival was 36-137 and 13.2-65 months in the surgical and nonsurgical groups, respectively, and the 5-year overall survival rate was 35.7-83 and 5.4%-50%, respectively, in these two groups. The meta-analysis demonstrated that there was no significant difference in liver tumor burden ( odds ratio [ OR] = 1.51, 95% CI: 0.59-3.89, P=0.39) or tumor grade ( OR = 2.88, 95% CI: 0.92-9.04, P=0.07) among patients who underwent surgery and nonsurgical therapy. Furthermore, patients who underwent an aggressive surgical approach appeared to have a higher tumor grade. However, the meta-analysis demonstrated that patients who underwent primary tumor resection had better overall survival ( P<0.001), with a pooled hazard ratio of 0.36 ( 95% CI: 0.30-0.45). No publication bias was detected. Conclusion: This meta-analysis demonstrates that the palliative resection of the primary tumor in patients with PNETs and unresectable liver metastases can increase survival, although a bias toward a more aggressive surgical approach in patients with better performance status, less advanced disease, or a tumor located in the body or tail of the pancreas appears likely. RCTs with longer follow-up periods are required to confirm the advantages of palliative primary tumor resection for PNETs.

Systematic Review of Resecting Primary Tumor in MNETs Patients with Unresectable Liver Metastases

Treatment of Primary Hepatic Neuroendocrine Tumors

Role of Palliative Resection of the Primary Pancreatic Neuroendocrine Tumor in Patients with Unresectable Metastatic Liver Disease: a Systematic Review and Meta-Analysis

Resection of Liver Metastases: A Treatment Provides a Long-Term Survival Benefit for Patients with Advanced Pancreatic Neuroendocrine Tumors: A Systematic Review and Meta-Analysis

The Role of Primary Tumor Resection in Patients With Pancreatic Neuroendocrine Tumors With Liver Metastases

Meta-analysis of Liver Resection Versus Nonsurgical Treatments for Pancreatic Neuroendocrine Tumors with Liver Metastases

Surgical Resection of Primary Tumor Improves Survival of Pancreatic Neuroendocrine Tumor with Liver Metastases.

Clinical Analysis of Gastroenteropancreatic Neuroendocrine Tumor with Liver Metastasis, Compared with Primary Hepatic Neuroendocrine Tumor.

Neuroendocrine Tumors of Unknown Primary in the Setting of Cytoreductive Hepatectomy

Primary Tumor Resection for Rectal Cancer With Unresectable Liver Metastases: A Chance to Cut Is a Chance for Improved Survival

The Prognostic Impact of Primary Tumor Resection in Pancreatic Neuroendocrine Tumors with Synchronous Multifocal Liver Metastases.

Impact of the extent of resection of neuroendocrine tumor liver metastases on survival: A systematic review and meta-analysis

Primary hepatic neuroendocrine carcinoma: report of two cases and literature review

Risk Factors Affecting Prognosis in Metachronous Liver Metastases from WHO Classification G1 and G2 Gastroenteropancreatic Neuroendocrine Tumors after Initial R0 Surgical Resection

Multi-Center, Randomized, Controlled, Open-Label Effectiveness Study Of Primary Tumor Resection Or Not In Asymptomatic Colorectal Cancer With Unresectable Metastatic Disease.

Management of Neuroendocrine Tumor Liver Metastases: Long-Term Outcomes and Prognostic Factors from a Large Prospective Database

The Effect of Primary Site, Functional Status and Treatment Modality on Survival in Gastroenteropancreatic Neuroendocrine Neoplasms with Synchronous Liver Metastasis: a US Population-Based Study

Distinct clinicopathological features of neuroendocrine liver metastases originating from the pancreas and rectum

Long-term Outcomes of Surgical Treatment for Pancreatic Neuroendocrine Neoplasm with Synchronous Hepatic Metastasis: A Multicenter Retrospective Cohort Study

Surgical management for non-functional pancreatic neuroendocrine neoplasms with synchronous liver metastasis: A consensus from the Chinese Study Group for Neuroendocrine Tumors (CSNET)

Prognostic factors influencing survival in small bowel neuroendocrine tumor with liver metastases